Aviceda Therapeutics

Aviceda Therapeutics

  • Founded: 2018
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2/Clin3
  • Therapy area: Geographic atrophy
  • Drug types: OPH, HEP, LNG, NEU, NEU
  • Lead product: AVD-104
  • Product link: https://www.avicedarx.com/pipeline.html
  • Funding: <10M



job board

Short description:

Next generation of glyco-immune therapeutics

Drug notes:

Also Clin0 DME, Clin0 other eye conditions; 4 undisclosed programs RD/Clin0 IPF, liver fibrosis, myelofibrosis, lung inflammation, neurodegeneration, neuroinflammation, solid tumors

Long description:

Aviceda Therapeutics is developing glyco-therapeutics that modulate immune system dysfunction. The human glycome is far more diverse than the proteome or genome and plays a role in regulating innate immune checkpoints. Aviceda is using their technology platform to engineer highly optimized glyco-ligands that can modulate the self-recognition receptors on immune cells and convert them to a resolution state. Aviceda’s lead candidate, AVD-103, is being developed to target various immune system responses that contribute to pathology associated with dry age-related macular degeneration. AVD-104 is one of several glyco-immune therapeutics Aviceda is developing that are delivered via biodegradable nanoparticles.


Aviceda Therapeutics
Sr. Director/VP, Biology and Translational Researc...
Belfast, Nothern Ireland|33 days ago
Aviceda Therapeutics
Senior/Principal Scientist, Glycochemistry/Carbohy...
Cambridge, Massachusetts|85 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com